M2M+Unit+III+Recommended+Reading

- Howlett, N. G., T. Taniguchi, S. Olson, B. Cox, Q. Waisfisz, C. De Die-Smulders, N. Persky, M. Grompe, H. Joenje, G. Pals, H. Ikeda, E. A. Fox, and A. D. D'Andrea (2002) Biallelic inactivation of BRCA2 in Fanconi anemia. Science 297:606-609. - Foster, B. A., H. A. Coffey, M. J. Morin, and F. Rastinejad. 1999. Pharmacological rescue of mutant p53 conformation and function. Science. 286:2507-2510. - Denissenko, M. F., A. Pao, M.-s. Tang, and G. P. Pfeifer. Preferential formation of Benzo[a]pyrene adducts at lung cancer mutational hotspots in p53. Science 274:430-432 (1996). - Druker, B. Perspectives on the development of a molecularly targeted agent. Cancer Cell 1, 31-36 (2002). - Sharma, S. V., and J. Settleman, 2007 Oncogene addiction: setting the stage for molecularly targeted cancer therapy. Genes Dev 21: 3214-3231. - Herceptin - NCI Targeted Therapies Tutorial - Cancer Genome Browser || 1 In the fifth edition, Chapter 2.1 (p. 43-54) and Chapter 11 (p. 371 - 418) mostly correlate to the readings suggested. =Clinical Vignettes= - Kim WY, Kaelin WG. Role of VHL gene mutation in human cancer. J Clin Oncol. 2004;22(24):4991-5004. - Kaelin WG. The von Hippel-Lindau tumor suppressor gene and kidney cancer. Clin Cancer Res. 2004 Sep 15;10(18 pt 2) 6290S-5S. ||  || General information on chronic kidney disease ||
 * || **Lehninger Principles of Biochemistry, 5****th** **Edition** || **Alberts et al Molecular Biology of the Cell, 4****th** **Edition** || **Thompson and Thompson Genetics in Medicine, 7****th** **Edition** || **Other** ||
 * Molecular Basis of Carcinogenesis ||  ||   || Chapter 16 (p. 461-484). || - Chasing the Cancer Demon
 * Membrane Structure ||  ||   ||   ||   ||
 * Composition of Cells || (4th Edition) p. 47-56; 369-411. 1 || p. 61-62; 112-113; 118; 583-588; 593-596; 636. ||  ||   ||
 * Cell Volume Regulation || (4th Edition) p. 56-58. 1 ||  ||   ||   ||
 * Membrane Potential I, II, III ||  || p. 631-634. ||   ||   ||
 * Acids, Bases & Buffers || p. 54-65. ||  ||   ||   ||
 * Membrane Fusion ||  || Chapter 13 (p. 711-767) ||   ||   ||
 * Membrane Transporters || (4th Edition) p. 389-411. 1 || p. 615-631. ||  ||   ||
 * Epithelial Transport ||  || p. 1066-1070. ||   ||   ||
 * Action Potential I, II & III ||  || p. 637-645 ||   ||   ||
 * Secretory Pathways I & II ||  ||   ||   ||   ||
 * Nucleus and Nuclear Import/Export ||  ||   ||   ||   ||
 * Protein Degradation ||  ||   ||   ||   ||
 * || **Reading** || **Electronic Resources** ||
 * Von Hippel-Lindau || - Shuin T, Yamazaki I, et al. Recent advances in ideas on the molecular pathology and clinical aspects of von Hippel-Lindau disease. Int J Clin Oncol. 2004; 9(4): 283-7.
 * Diabetic Ketoacidosis (DKA) ||  || Barbara Davis Center for Childhood Diabetes ||
 * Multiple Sclerosis ||  ||   ||
 * Cholera ||  || @http://www.who.int/csr/don/en ||
 * Hyperkalemia || - Feehally, J, Floege J, Johnson J. Disorders of potassium metabolism in Comprehensive Clinical Nephrology, 3rd edition. Mosby Inc. 2007, Philadelphia PA. || Information on potassium in the diet

=Bench to Bedside=


 * || **Required Materials** ||
 * Ethics of Human Research || The Belmont Report ||